Eisai Co. Ltd. (ESAIY PINK) stock market data APIs
$7.3803
-0.13(-1.8%)
as of October 7, 2026
Try our APIs with
free plan!
Eisai Co. Ltd. Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
7.3803
Open
7.2479
High
7.403
Low
7.2471
52 wk Range
5.5974-8.14
Market Cap
8 286 M
P/E Ratio
31.913
Shares Outstanding
1 129 M
Revenue
857 057 M
EPS
0.1015
Dividends (Yield)
0.0347
Beta
-0.085
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd. data using free add-ons & libraries
Get Eisai Co. Ltd. Fundamental Data
Eisai Co. Ltd. Fundamental data includes:
- Net Revenue: 857 057 M
- EBITDA: 96 127 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd. News
New
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
Merck MRK announced that the FDA has expanded the label of its oral cancer drug Welireg (belzutifan) for a third indication in advanced renal cell carcinoma (RCC), the most common type of adult kidney...
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Biogen BIIB has been undergoing a major transformation. The company has long been seeing declining sales of its key multiple sclerosis ("MS") due to generic competition for Tecfidera globally, biosimi...
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer's disease, while Biogen also published Phase 3 VALIANT adolescen...
Leqembi® Pen subcutaneous formulation approved in Japan
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen...
Get Eisai Co. Ltd. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.